Jennifer R. Brown, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, outlines the preliminary results of the Phase I trial of ibrutinib combined with the PI3K-delta specific inhibitor, TGR-1202 in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). She highlights the significance of the results, as this is the first time BTK and PI3K inhibitors have been combined. The combined treatment was well tolerated and resulted in relatively low toxicity. The maximum dose was 800 mg daily for TGR-1202 (i.e. recommended Phase II dose, RP2D), with ibrutinib used at the approved CLL dose of 420 mg, 560 mg for MCL. Dr Brown concludes that efficacy looks promising and the CLL patients in particular, are doing well. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.